Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 30

1.

Molecular basis of USP7 inhibition by selective small-molecule inhibitors.

Turnbull AP, Ioannidis S, Krajewski WW, Pinto-Fernandez A, Heride C, Martin ACL, Tonkin LM, Townsend EC, Buker SM, Lancia DR, Caravella JA, Toms AV, Charlton TM, Lahdenranta J, Wilker E, Follows BC, Evans NJ, Stead L, Alli C, Zarayskiy VV, Talbot AC, Buckmelter AJ, Wang M, McKinnon CL, Saab F, McGouran JF, Century H, Gersch M, Pittman MS, Marshall CG, Raynham TM, Simcox M, Stewart LMD, McLoughlin SB, Escobedo JA, Bair KW, Dinsmore CJ, Hammonds TR, Kim S, Urbé S, Clague MJ, Kessler BM, Komander D.

Nature. 2017 Oct 26;550(7677):481-486. doi: 10.1038/nature24451. Epub 2017 Oct 18.

2.

HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.

Kirouac DC, Du J, Lahdenranta J, Onsum MD, Nielsen UB, Schoeberl B, McDonagh CF.

PLoS Comput Biol. 2016 Apr 1;12(4):e1004827. doi: 10.1371/journal.pcbi.1004827. eCollection 2016 Apr.

3.

Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers.

Kirouac DC, Lahdenranta J, Du J, Yarar D, Onsum MD, Nielsen UB, McDonagh CF.

CPT Pharmacometrics Syst Pharmacol. 2015 Mar;4(3):e00019. doi: 10.1002/psp4.19. Epub 2015 Mar 4.

4.

Heregulin-ErbB3-Driven Tumor Growth Persists in PI3 Kinase Mutant Cancer Cells.

Yarar D, Lahdenranta J, Kubasek W, Nielsen UB, MacBeath G.

Mol Cancer Ther. 2015 Sep;14(9):2072-80. doi: 10.1158/1535-7163.MCT-15-0075. Epub 2015 Jun 26.

5.

Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.

Kirouac DC, Du JY, Lahdenranta J, Overland R, Yarar D, Paragas V, Pace E, McDonagh CF, Nielsen UB, Onsum MD.

Sci Signal. 2013 Aug 13;6(288):ra68. doi: 10.1126/scisignal.2004008. Erratum in: Sci Signal. 2014 Sep 30;7(345):er5.

PMID:
23943608
6.

Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948).

Raut CP, Boucher Y, Duda DG, Morgan JA, Quek R, Ancukiewicz M, Lahdenranta J, Eder JP, Demetri GD, Jain RK.

PLoS One. 2012;7(2):e26331. doi: 10.1371/journal.pone.0026331. Epub 2012 Feb 7.

7.

Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.

Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, di Tomaso E.

Cancer Res. 2010 May 1;70(9):3483-93. doi: 10.1158/0008-5472.CAN-09-3107. Epub 2010 Apr 20.

8.

A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK.

Cancer Res. 2009 Jul 1;69(13):5296-300. doi: 10.1158/0008-5472.CAN-09-0814. Epub 2009 Jun 23.

9.

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study.

Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA, Sindhwani V, Blaszkowsky LS, Yoon SS, Lahdenranta J, Bhargava P, Meyerhardt J, Clark JW, Kwak EL, Hezel AF, Miksad R, Abrams TA, Enzinger PC, Fuchs CS, Ryan DP, Jain RK.

J Clin Oncol. 2009 Jun 20;27(18):3027-35. doi: 10.1200/JCO.2008.20.9908. Epub 2009 May 26.

10.

Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.

Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, Lahdenranta J, Chung DC, Fischman AJ, Lauwers GY, Shellito P, Czito BG, Wong TZ, Paulson E, Poleski M, Vujaskovic Z, Bentley R, Chen HX, Clark JW, Jain RK.

J Clin Oncol. 2009 Jun 20;27(18):3020-6. doi: 10.1200/JCO.2008.21.1771. Epub 2009 May 26.

11.

Edema control by cediranib, a vascular endothelial growth factor receptor-targeted kinase inhibitor, prolongs survival despite persistent brain tumor growth in mice.

Kamoun WS, Ley CD, Farrar CT, Duyverman AM, Lahdenranta J, Lacorre DA, Batchelor TT, di Tomaso E, Duda DG, Munn LL, Fukumura D, Sorensen AG, Jain RK.

J Clin Oncol. 2009 May 20;27(15):2542-52. doi: 10.1200/JCO.2008.19.9356. Epub 2009 Mar 30.

12.

Endothelial nitric oxide synthase mediates lymphangiogenesis and lymphatic metastasis.

Lahdenranta J, Hagendoorn J, Padera TP, Hoshida T, Nelson G, Kashiwagi S, Jain RK, Fukumura D.

Cancer Res. 2009 Apr 1;69(7):2801-8. doi: 10.1158/0008-5472.CAN-08-4051. Epub 2009 Mar 24.

13.

A ligand peptide motif selected from a cancer patient is a receptor-interacting site within human interleukin-11.

Cardó-Vila M, Zurita AJ, Giordano RJ, Sun J, Rangel R, Guzman-Rojas L, Anobom CD, Valente AP, Almeida FC, Lahdenranta J, Kolonin MG, Arap W, Pasqualini R.

PLoS One. 2008;3(10):e3452. doi: 10.1371/journal.pone.0003452. Epub 2008 Oct 20.

14.

Targeted induction of lung endothelial cell apoptosis causes emphysema-like changes in the mouse.

Giordano RJ, Lahdenranta J, Zhen L, Chukwueke U, Petrache I, Langley RR, Fidler IJ, Pasqualini R, Tuder RM, Arap W.

J Biol Chem. 2008 Oct 24;283(43):29447-60. doi: 10.1074/jbc.M804595200. Epub 2008 Aug 21.

15.

Targeting PDGF signaling in carcinoma-associated fibroblasts controls cervical cancer in mouse model.

Jain RK, Lahdenranta J, Fukumura D.

PLoS Med. 2008 Jan 29;5(1):e24. doi: 10.1371/journal.pmed.0050024. No abstract available.

16.

The original Pathologische Anatomie Leiden-Endothelium monoclonal antibody recognizes a vascular endothelial growth factor binding site within neuropilin-1.

Jaalouk DE, Ozawa MG, Sun J, Lahdenranta J, Schlingemann RO, Pasqualini R, Arap W.

Cancer Res. 2007 Oct 15;67(20):9623-9.

17.

Treatment of hypoxia-induced retinopathy with targeted proapoptotic peptidomimetic in a mouse model of disease.

Lahdenranta J, Sidman RL, Pasqualini R, Arap W.

FASEB J. 2007 Oct;21(12):3272-8. Epub 2007 May 18.

PMID:
17513561
18.

Ligand-directed surface profiling of human cancer cells with combinatorial peptide libraries.

Kolonin MG, Bover L, Sun J, Zurita AJ, Do KA, Lahdenranta J, Cardó-Vila M, Giordano RJ, Jaalouk DE, Ozawa MG, Moya CA, Souza GR, Staquicini FI, Kunyiasu A, Scudiero DA, Holbeck SL, Sausville EA, Arap W, Pasqualini R.

Cancer Res. 2006 Jan 1;66(1):34-40.

19.

Development of a ligand-directed approach to study the pathogenesis of invasive aspergillosis.

Lionakis MS, Lahdenranta J, Sun J, Liu W, Lewis RE, Albert ND, Pasqualini R, Arap W, Kontoyiannis DP.

Infect Immun. 2005 Nov;73(11):7747-58.

20.

Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands.

Arap MA, Lahdenranta J, Mintz PJ, Hajitou A, Sarkis AS, Arap W, Pasqualini R.

Cancer Cell. 2004 Sep;6(3):275-84.

21.

Aminopeptidase A is a functional target in angiogenic blood vessels.

Marchiò S, Lahdenranta J, Schlingemann RO, Valdembri D, Wesseling P, Arap MA, Hajitou A, Ozawa MG, Trepel M, Giordano RJ, Nanus DM, Dijkman HB, Oosterwijk E, Sidman RL, Cooper MD, Bussolino F, Pasqualini R, Arap W.

Cancer Cell. 2004 Feb;5(2):151-62.

22.

Model of unidirectional transluminal gene transfer.

Arap MA, Lahdenranta J, Hajitou A, Marini FC 3rd, Wood CG, Wright KC, Fueyo J, Arap W, Pasqualini R.

Mol Ther. 2004 Feb;9(2):305-10.

23.

Steps toward mapping the human vasculature by phage display.

Arap W, Kolonin MG, Trepel M, Lahdenranta J, Cardó-Vila M, Giordano RJ, Mintz PJ, Ardelt PU, Yao VJ, Vidal CI, Chen L, Flamm A, Valtanen H, Weavind LM, Hicks ME, Pollock RE, Botz GH, Bucana CD, Koivunen E, Cahill D, Troncoso P, Baggerly KA, Pentz RD, Do KA, Logothetis CJ, Pasqualini R.

Nat Med. 2002 Feb;8(2):121-7.

PMID:
11821895
24.

Biopanning and rapid analysis of selective interactive ligands.

Giordano RJ, Cardó-Vila M, Lahdenranta J, Pasqualini R, Arap W.

Nat Med. 2001 Nov;7(11):1249-53.

PMID:
11689892
25.

An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration.

Lahdenranta J, Pasqualini R, Schlingemann RO, Hagedorn M, Stallcup WB, Bucana CD, Sidman RL, Arap W.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10368-73.

26.

CD13/APN is activated by angiogenic signals and is essential for capillary tube formation.

Bhagwat SV, Lahdenranta J, Giordano R, Arap W, Pasqualini R, Shapiro LH.

Blood. 2001 Feb 1;97(3):652-9.

27.

Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis.

Pasqualini R, Koivunen E, Kain R, Lahdenranta J, Sakamoto M, Stryhn A, Ashmun RA, Shapiro LH, Arap W, Ruoslahti E.

Cancer Res. 2000 Feb 1;60(3):722-7.

28.

Integrin-binding peptides derived from phage display libraries.

Koivunen E, Restel BH, Rajotte D, Lahdenranta J, Hagedorn M, Arap W, Pasqualini R.

Methods Mol Biol. 1999;129:3-17. No abstract available.

PMID:
10494554
29.

Identification of receptor ligands with phage display peptide libraries.

Koivunen E, Arap W, Rajotte D, Lahdenranta J, Pasqualini R.

J Nucl Med. 1999 May;40(5):883-8. Review.

30.

SEM1, a homologue of the split hand/split foot malformation candidate gene Dss1, regulates exocytosis and pseudohyphal differentiation in yeast.

Jäntti J, Lahdenranta J, Olkkonen VM, Söderlund H, Keränen S.

Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):909-14.

Supplemental Content

Loading ...
Support Center